Hernandez I, et al. - Researchers analyzed trends in Medicaid prices, market share, and long-acting insulin expenditure in this investigation (2006-2018). From 2001 to 2014, insulin prices rose by 320%, partly due to limited competition and generic entry barriers. Before 2015, insulin glargine and insulin detemir were the only two long-acting insulins available. In December 2015, the FDA approved a biosimilar for insulin glargine. Although approved as a new drug, it was the first replacement for Lantus, rather than through the biosimilar pathway. The approval of Basaglar coincided with approvals for highly concentrated insulin glargine, ultra-long-acting insulin degludec, and insulin glargine and lixisenatide combinations.